<DOC>
	<DOC>NCT00347737</DOC>
	<brief_summary>The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).</brief_summary>
	<brief_title>The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL</brief_title>
	<detailed_description>Research subjects participation is about 6 months. Subjects will give themselves daily injections of teriparatide after instruction on technique.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide Patients with diabetes mellitus current smokers patients with a history of organ transplantation Patients currently of previously on glucocorticoid therapy within the past year Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater) Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis History of radiation therapy Patients pregnant or nursing History of bone metastasis or skeletal malignancies History of hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>